Navigation Links
Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014
Date:7/25/2014

NEWARK, Calif., July 25, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will release second quarter fiscal year 2014 financial results after the market closes on Wednesday, August 6, 2014. The Company will host a conference call beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its results.

Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be available via a live webcast on the investor relations section of Depomed's website at http://www.depomed.com. Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.

About Depomed

Depomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders.  Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. CAMBIA® (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults.  Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and various partner product candidates are formulated with Depomed's proven, proprietary Acuform®<
'/>"/>

SOURCE Depomed, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
2. Depomed To Present At Jefferies 2012 Global Health Care Conference
3. Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
4. Depomed To Present At JMP Securities 7th Annual Healthcare Conference
5. Depomed To Report Second Quarter Fiscal Year 2012 Financial Results On Thursday, August 2, 2012
6. Depomed To Present At Stifel Nicolaus 2012 Healthcare Conference
7. Depomed To Present At Morgan Stanley 2012 Healthcare Conference
8. Depomed To Present At UBS Global Life Sciences Conference
9. Depomed To Report Third Quarter Fiscal Year 2012 Financial Results On Monday, November 5, 2012
10. Depomed Reports Third Quarter Financial Results
11. Depomed To Present At Lazard 2012 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015  PinnacleHealth CardioVascular Institute enrolled the first patient ... the United States in a trial assessing ... for blockages in the main artery of the leg. The ... potentially less risk for stent fracture or re-narrowing after the ... multicenter clinical trial of the BioMimics 3D Stent System and ...
(Date:8/27/2015)... YORK , August 27, 2015 ... published by Persistence Market Research titled "Global Market ... Witness Highest Growth by 2021", the urinary catheters market is ... the end of 2015. It is anticipated to ... 2021, to reach US$1,755.0 Mn by 2021. ...
(Date:8/27/2015)... 2015  QB3@953—a San Francisco ... California (UC) research institute and biotech accelerator— today ... identify and facilitate collaborations to translate early drug ... The agreement formalizes a relationship between QB3@953 ... and creates a new channel for DPAc to ...
Breaking Medicine Technology:First Pennsylvania Patient Treated in Landmark Vascular Study 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2
... Berger Health System, recognized as one of the ... to AutoCarousel® HD by Talyst, a leader of pharmacy ... has a built-to-last 10 years guarantee. Berger ... is also implementing AutoPharm®, AutoPack™ and AutoLabel® to help ...
... Lineagen, Inc., an innovative molecular diagnostics company focused on ... nonprofit subsidiary of the National Multiple Sclerosis Society, today ... validation of a blood-based assay for multiple sclerosis (MS). ... test that can aid clinicians in diagnosing MS, distinguishing ...
Cached Medicine Technology:Berger Health System Partners With Pharmacy Automation Leader to Improve Patient Safety 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 2Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 3Lineagen and Fast Forward Collaborate to Develop Gene and Biomarker-Based Clinical Assays for Multiple Sclerosis 4
(Date:8/27/2015)... ... August 27, 2015 , ... Cytovance® Biologics, ... biopharmaceutical contract development manufacturing company (CDMO), announced today that it has entered into ... in cash. , The addition of Cytovance Biologics to Hepalink USA ...
(Date:8/27/2015)... ... 27, 2015 , ... Susan Harris and the team at LifeStream ... to pre- and post-menopause, chemotherapy, and child birth. , The MonaLisa Touch ... to the vaginal tissue, revitalizing cells so they make more collagen, an essential component ...
(Date:8/27/2015)... Rocky Hill, CT (PRWEB) , ... August 27, 2015 , ... ... Portal Companies List. , “The companies selected have the platforms required not only to ... training,” said Ken Taylor, President of Training Industry, Inc. , For six consecutive ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... firm that helps libraries, publishers and companies leverage key operational, technical, business ... the VIVO Project. Gunter Media Group, Inc., will provide VIVO related services ...
(Date:8/27/2015)... Newport Beach, CA (PRWEB) , ... August 27, ... ... services and products, announced today that the new issue of Chairside® magazine, its ... the latest issue, Volume 10, Issue 3, as well as past issues of ...
Breaking Medicine News(10 mins):Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3Health News:DuraSpace Selects Gunter Media Group, Inc. as a Registered Service Provider for VIVO 2Health News:DuraSpace Selects Gunter Media Group, Inc. as a Registered Service Provider for VIVO 3Health News:Glidewell Laboratories Releases Latest Issue of Restorative Dentistry Magazine Chairside in Print and Online 2Health News:Glidewell Laboratories Releases Latest Issue of Restorative Dentistry Magazine Chairside in Print and Online 3
... , , BATESVILLE, Ind., and ... today announced a strategic partnership agreement to integrate the Radianse ... system. With this move, Hill-Rom intends to extend its ... financial and technical obstacles for health care customers as they ...
... NOVATO, Calif., Sept. 2 BioMarin Pharmaceutical Inc. (Nasdaq: ... Chief Financial Officer of BioMarin, will present a company update at the ... at 4:25 p.m. ET. , , Interested ... the investor section of the BioMarin website, www.BMRN.com . ...
... SOMERSET, N.J., Sept. 2 Meda Pharmaceuticals ... (FDA) has approved ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, for ... rhinitis (SAR and PAR). New ASTEPRO Nasal Spray 0.15% ... for patients who suffer from seasonal allergies. ASTEPRO Nasal Spray ...
... /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin Board: RNER; "the Company") announced ... publicized the creation of "Opinions of the,CPC Central Committee and ... Health Care System" ("Opinion"). , The ... a,doctor more easily. Reduced cost is the short-term goal and ...
... , , , , ... Mass., Sept. 2 /PRNewswire-FirstCall/ -- ... company that is developing and marketing Levulan(R) Photodynamic Therapy (PDT) and ... Bob Doman, President and Chief Executive Officer, will present a corporate ...
... , , , ... , a medical device company, today announced that its ... the U.S. Food and Drug Administration (FDA) for the direct delivery ... may be in the treatment of cancer. , , ...
Cached Medicine News:Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 3Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 4Health News:BioMarin to Present at the Thomas Weisel Partners Healthcare Conference 2Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 2Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 3Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 4Health News:MEDA Receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine 5Health News:RainEarth (RNER) Complies with Chinese Medical Service Reforms to Provide Better and Cheaper Blood Dialysis 2Health News:RainEarth (RNER) Complies with Chinese Medical Service Reforms to Provide Better and Cheaper Blood Dialysis 3Health News:DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 2Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 3Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 4
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Similar to Model 530, but just 37 inches long and with only one drape....
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Medicine Products: